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The constitutive procoagulant and
hypofibrinolytic state in patients with intermittent
claudication due to infrainguinal disease
significantly improves with percutaneous
transluminal balloon angioplasty
Simon D. Hobbs, MBChB,a Tim Marshall, MSc,b Chris Fegan, MD,c Donald J. Adam, MD,a
and Andrew W. Bradbury, MD,a Birmingham, United Kingdom
Background: Patients with intermittent lower limb claudication (IC) exhibit a prothrombotic diathesis that is acutely
exacerbated by exercise. This may occur because of ischemia/reperfusion injury within the leg muscles during walking and
may contribute to the increased risk of thrombotic vascular events in this group of patients. This randomized study
compared the effect of lower limb revascularization by percutaneous transluminal balloon angioplasty (PTA), supervised
exercise, and best medical therapy (BMT) alone on this prothrombotic state.
Methods: Twenty-three patients (16 men and 7 women; median age, 67 years; range, 57-77 years) with IC due to
infrainguinal disease were randomized to receive BMT alone (n  7), BMT plus PTA (n  9), or BMT plus supervised
exercise (n  7) as part of the Health Technology Assessment–funded EXercise vs Angioplasty in Claudication Trial
(EXACT). Patients were assessed at baseline and at 3 and 6 months. Thrombin-antithrombin complex (TAT) was
determined as a marker of thrombin generation, and plasminogen activator inhibitor (PAI) antigen was determined as a
marker of fibrinolysis. Increased TAT indicates a procoagulant state, and increased PAI antigen indicates a hypofibrino-
lytic state.
Results: At 6 months, subjects randomized to BMT plus PTA demonstrated a significant improvement in ankle-brachial
pressure index (P .013) and maximal walking distance (P .008), a significant decline in resting thrombin generation
(median [interquartile range] TAT, 6.4 g/L [2.7-13.5 g/L] to 1.5 g/L [0.3-2.9 g/L]; P  .038), and an
improvement in resting fibrinolysis (median [interquartile range] PAI-1, 10.0 ng/mL [1.0-20.5 ng/mL] to 1.0 ng/mL
[1.0-14.8 ng/mL]; P .043). There was no significant change in any of these parameters in patients randomized to BMT
plus supervised exercise or to BMT alone.
Conclusions: The addition of lower limb revascularization by PTA to BMT in patients with IC due to infra-inguinal
disease results in a medium-term improvement in the resting procoagulant and hypofibrinolytic state. This may translate
into a reduction in morbidity and mortality from thrombotic vascular events in this group of patients. ( J Vasc Surg 2006;
43:40-46.)Intermittent claudication (IC) is a common condition
that affects 5% of the middle-aged (55-74 years old) white
population1 and is a common cause of immobility, social
exclusion, and impaired health-related quality of life.2 Pa-
tients with IC have an annual mortality rate that is three to
four times higher than that of an age- and sex-matched
nonclaudicant population.3,4 Most of this excess mortality
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40is due to thrombotic vascular events—namely, myocardial
infarction, ischemic stroke, and critical limb ischemia. Pre-
vious work from this institution has demonstrated that
exercise in individuals with IC is associated with a pro-
thrombotic response characterized by excessive thrombin
generation and relative hypofibrinolysis.5 It has been pos-
tulated that the repeated ischemia/reperfusion injury (IRI)
occurring in the lower limb of the exercising claudicant
contributes to this prothrombotic diathesis and may, in
turn, expose the individual to an increased risk of throm-
botic vascular events.5 We hypothesized that lower limb
revascularization by percutaneous transluminal balloon an-
gioplasty (PTA), in addition to best medical therapy
(BMT), would reduce the IRI, thus resulting in an attenu-
ation of the prothrombotic response. The aim of this study,
therefore, was to compare the effects of BMT only, BMT
plus supervised exercise, and BMT plus infrainguinal PTA
on coagulation and fibrinolysis in subjects with IC due to
infrainguinal disease entered into the UK Health Technol-
ogy Assessment (HTA)-funded multicenter EXercise vs
Angioplasty in Claudication Trial (EXACT).
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Exercise vs angioplasty in claudication trial.
EXACT was a UK HTA program multicenter randomized
controlled trial comparing the adjuvant benefits of super-
vised exercise and PTA over BMT in patients with mild to
moderate IC (defined as an absolute claudication distance
[ACD] of 50-500 m on a treadmill) due to infrainguinal
disease. Briefly, suitable patients were those who (1) had
clinically and hemodynamically confirmed mild to moder-
ate IC due to infrainguinal disease as their exercise-limiting
diagnosis and (2) were suitable for unilateral infrainguinal
PTA and participation in a dedicated, trial-funded, super-
vised exercise class. Subjects were excluded if they had
significant aortoiliac disease, equally severe bilateral symp-
toms (and, therefore, were unsuitable for unilateral angio-
plasty), or previous ipsilateral infrainguinal intervention or
were unable to exercise to ACD on the treadmill (eg,
limited by shortness of breath).
All patients underwent a standard vascular examina-
tion, including measurement of ankle-brachial pressure in-
dex (ABPI) and a treadmill test (speed 3 km/h at a fixed
10% gradient) to ACD. The diagnosis of IC was confirmed
by using the Edinburgh claudication questionnaire6 com-
bined with a finding of a resting ABPI0.9 or a significant
decrease in ABPI after the treadmill test in the affected leg.7
Patients with confirmed IC due to atherosclerotic periph-
eral arterial disease (PAD) were stabilized on BMT, as
previously described,8 for 3 to 6 months before consider-
ation for trial entry.
All patients deemed suitable for EXACT at their first
visit were further assessed with duplex ultrasonography
(Philips ATLHDI-5000; PhilipsMedical Systems, Reigate,
UK) by an experienced vascular technician. Duplex find-
ings were discussed in a multidisciplinary meeting attended
by vascular surgeons and interventional radiologists. All
TransAtlantic Inter-Society Consensus femoropopliteal
category A and B lesions were considered appropriate for
PTA.9 Certain category C lesions were also considered
appropriate in the absence of a flush superficial femoral
artery occlusion or diffuse superficial femoral artery disease.
After 3 to 6 months of stabilization on BMT, all potentially
eligible patients were reassessed to monitor progress and to
determine compliance with BMT. At this point, patients
were invited to take part in EXACT if they
1. Remained, in the patient’s opinion, “unacceptably
symptomatic.”
2. Still had a ACD of 50 to 500 m on treadmill assessment.
3. Had infrainguinal disease amenable to unilateral PTA.
4. Were suitable for enrollment within the supervised ex-
ercise program.
Subjects underwent central randomization to continue
with BMT alone, to receive BMT plus supervised exercise,
or to receive BMT plus PTA. Those randomized to super-
vised exercise were enrolled in a 12-week course of twice-
weekly 1-hour structured exercise sessions led by a vascular
nurse specialist and a physiotherapist, and subjects random-ized to PTA underwent the procedure within 12 weeks of
randomization.
Between September 2002 and July 2004, 372 patients
referred by their primary care physicians for investigation
and treatment of suspected claudication were screened for
entry into EXACT. Of these, 23 (6%) patients gave fully
informed written consent to be randomized into the
present study (Table I). The main reasons for excluding
willing patients were one or more of the following: incor-
rect diagnosis in primary care, equally severe bilateral symp-
toms (patients were therefore judged inappropriate for
unilateral PTA), significant aortoiliac disease, maximum
claudication distance less than 50 m or more than 500 m
(outside EXACT trial limits), no lesion suitable for PTA
on duplex scan, and previous ipsilateral intervention.
Nine subjects were randomized to receive BMT plus
PTA; seven, to receive BMT plus supervised exercise; and
seven, to remain on BMT alone. Subjects in the three
treatment groups were well matched for age, smoking
status, diabetes, lipid profile, antiplatelet therapy, statin
therapy, angiotensin-converting enzyme inhibitor therapy,
ABPI, initial claudication distance (ICD), ACD, and the
TransAtlantic Inter-Society Consensus category of the tar-
get leg lesion. However, subjects randomized to supervised
exercise were significantly more likely to be receiving anti-
hypertensive medication than those randomized to PTA
(P  .034; Fisher exact test). Subjects who underwent PTA
had the procedure performed a median of 39 days (inter-
quartile range [IQR], 28-77 days) after randomization.
One subject in the supervised exercise group withdrew
from the study shortly after randomization; the remainder
completed their 3- and 6-month follow-up assessments.
Exercise program. The exercise program was devised
by the Faculty of Health and Exercise at University College
Worcester to include group activity and a personalized
exercise prescription. Although there is some evidence that
thrice-weekly sessions are superior to twice-weekly sessions,
the evidence is not particularly strong because of the small
number of trial participants in the assessed studies.10 It was
therefore believed that a twice-weekly program would offer
the optimal balance between therapeutic benefit and, im-
portantly, compliance with the regimen. The 1-hour exer-
cise program encouraged subjects to perform exercise of
moderate intensity in accordance with the American Col-
lege of Sports Medicine guidelines and has been validated
for use in subjects with IC. After a 5-minute warm-up,
subjects underwent a circuit sequence of exercises. This
sequence involved a shuttle walk at moderate to hard pace;
paired toe raising to heel raising, with chair support for
balance; continuous sitting and standing from chair; spot
marching with high knees, swinging arms; arm exercises
from the upright sitting position (side arm raising, alternate
arm vertical pushing, and side bent-arm lift); shuttle walk at
moderate to hard pace; knee bends with chair support for
balance; alternate heel raising (left/right) with chair sup-
port for balance; step-ups on bench or stairs; and arm
exercises from the upright sitting position (straight side arm
small backward circling, double arm vertical pushing, and
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minutes of activity at each station followed by 2 minutes of
rest. On days when not attending the supervised sessions,
subjects were asked to perform the exercise program unsu-
pervised at home. Training logs were kept to detail the
number of repetitions performed and the maximal heart
rate at each station to ensure an adequate training effect.
Studies of coagulation and fibrinolysis. After local
ethics approval, subjects randomized into EXACT at our
center were additionally enrolled into this substudy assess-
ing the effects of adjunctive treatment on coagulation and
fibrinolysis. Subjects were assessed immediately after ran-
domization and at 3 and 6 months after randomization.
Before each visit, subjects were asked to refrain from smok-
ing or eating a heavy meal and to avoid unaccustomed
exercise in the preceding 24 hours. All visits took place
between 8:30 and 9:00 AM, and subjects were transported
to the hospital by taxi and then transferred to the Vascular
InvestigationUnit by wheelchair to avoid walking. Subjects
rested for 60 minutes before undergoing venipuncture
from an antecubital fossa vein without tourniquet. Blood
was collected into sodium citrate tubes and was immedi-
ately centrifuged at 4°C for 15 minutes at 2000g. The
resultant plasma was stored at 80°C for later batch anal-
ysis. ABPI was measured in both legs by using a Mini
Dopplex with an 8-MHz probe (Huntleigh Diagnostics,
Cardiff, UK). For each leg, the highest recorded pressure
from the three ankle vessels (anterior tibial, posterior tibial,
and perforating peroneal) was used to determine the ABPI.
Subjects then exercised with a standard treadmill exercise
Table I. Baseline demographic data, medications, and dis
Variable BMT
n 7
Age (y) 77 (56-78) 67 (5
Sex (M:F) 4:3 6
Smoking status
Current smoker 1
Ex-smoker 5
Never smoker 1
Diabetes 4
Medication
Antiplatelet agent 7
Statin 7
Antihypertensive 6
ACE inhibitor 4
Baseline treated lipid profile
Total cholesterol 4.6 (4.1-4.9) 4.4 (4
Triglycerides 1.7 (1.5-3.2) 1.6 (1
TASC category of lesion9
A 3
B 2
C 2
Figures represent the number of cases or median values (interquartile range
BMT, Best medical therapy; SE, supervised exercise; PTA, percutaneous tra
enzyme; TASC, TransAtlantic Inter-Society Consensus.
*Analysis of variance.
†Fisher exact test.test (3 km/h at 10% incline) to their ACD or to 1000 m (atfollow-up visits), whichever was soonest. The distance
when claudication pain was first perceived was recorded as
the ICD. A further venipuncture was performed 3 minutes
after completion of the treadmill test from an antecubital
vein different from that used for the first venipuncture, and
the plasma was extracted and stored as described previ-
ously.
Thrombin generation cannot be directly measured be-
cause, under pathologic conditions, less than 1% of circu-
lating prothrombin is transformed to thrombin, and it is
rapidly inactivated by antithrombin III. Thrombin genera-
tion can, however, be measured indirectly by measuring the
amount of inactivated thrombin, namely, the thrombin-
antithrombin (TAT) complex.11 Plasma levels of TAT
(Dade-Behring, Marburg, Germany) were determined by
enzyme-linked immunosorbent assay (ELISA) on the rest-
ing and postexercise samples at baseline and 6 months. The
analysis was manual except for the reading, which was
performed on an ELISA workstation (Triturus, Grifols,
Cambridge, UK). Samples were analyzed as one batch, and
the intra-assay coefficient of variation was 5%.
Fibrinolytic function can be examined by measuring
plasminogen activator inhibitor (PAI)-1) antigen levels. A
hypofibrinolytic state is associated with increased PAI-1
antigen levels. Because our previous studies had not dem-
onstrated an acute change in fibrinolysis with exercise, PAI
antigen levels (Technoclone, Vienna, Austria) were deter-
mined by ELISA on the resting samples only, at baseline
and 3 and 6 months. TAT and PAI-1 antigen were chosen
for this study because our pilot studies have shown these to
severity of the enrolled subjects (n  23)
PTA Total P value
9 23
) 67 (57-76) 67 (57-77) .85*
6:3 15:7
2 6 NS†
6 15 NS†
1 2 NS†
2 10 NS†
9 23 NS†
9 23 NS†
4 18 .034†
2 11 NS†
.9) 4.4 (4.0-4.8) 4.4 (4.1-4.8) .74*
.8) 1.6 (1.1-2.8) 1.6 (1.1-2.8) .90*
2 9 NS†
3 7 NS†
4 7 NS†
inal balloon angioplasty; NS, not significant; ACE, angiotensin-convertingease
SE
7
8-71
:1
3
4
0
4
7
7
7
5
.1-4
.1-2
4
2
1
).
nslumbe significantly increased in claudicants when compared
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was not measured because we were unable to find an
activity assay that produced reproducible results in our
hands. All assays were performed by a UK National Health
Service–accredited laboratory.
Sample size calculation and statistical analysis. For
the study to support the working hypothesis described
previously, it needed to have the power to be able to show
significant improvements in thrombin formation and fibri-
nolysis in patients undergoing PTA. On the basis of pilot
data, 21 subjects (7 per group) were required to detect a
75% reduction in TAT in the treatment groups with 80%
power and a P value of.05. Data were analyzed with SPSS
version 11.0.1 for Windows (SPSS Inc, Chicago, Ill).
Groups were compared at baseline by using the analysis of
variance (ANOVA) test for continuous data and the Fisher
exact test for categorical data. Changes over time were
analyzed by using the Wilcoxon signed rank test. A P value
.05 was considered statistically significant.
RESULTS
Change in disease severity
Ankle-brachial pressure index. Over the 6-month
study period, there was a significant improvement in ABPI
in the target leg in the group as a whole. Subgroup analysis
showed that the only subjects to demonstrate an improve-
ment were those in the BMT plus PTA group. Subjects in
the BMT-alone and BMT plus supervised exercise groups
had no significant changes in ABPI (Table II).
ICD and ACD. There was a significant improvement
in ICD and ACD for the subjects as a whole over the
6-month study period. However, on subgroup analysis, the
only subjects to demonstrate significant improvements in
walking distance were those randomized to BMT plus
Table II. Changes in ankle-brachial pressure index, initial
for all subjects and by subgroup over the 6-month study p
Variable Baseline
Target leg ABPI
All subjects 0.70 (0.59-0.79)
BMT 0.74 (0.55-0.80)
SE 0.66 (0.48-0.84)
PTA 0.69 (0.63-0.76)
ICD
All subjects 57 (37-101)
BMT 47 (30-118)
SE 59 (35-63)
PTA 84 (43-127)
ACD
All subjects 127 (79-201)
BMT 84 (79-227)
SE 111 (69-237)
PTA 185 (110-245)
Figures represent median values (interquartile range).
ABPI, Ankle-brachial pressure index; BMT, best medical therapy; SE, super
claudication distance; ACD, absolute claudication distance.
*Wilcoxon signed rank test.PTA.Thrombin generation: TAT
There were no significant differences in TAT levels
among the three groups at baseline (P  .16; ANOVA).
Resting TAT levels correlated with ICD (Spearman coeffi-
cient, 0.486; P  .022) but no other clinical parameter.
Taking the study population as a whole, a significant acute
increase in TAT after exercise to ACD was observed at
baseline and 3 and 6 months (median [IQR] TAT: base-
line, 3.1 g/L [1.8-9.3 g/L] to 4.8 g/L [2.6-15.8
g/L], P  .006; 3 months, 2.8 g/L [1.3-4.7 g/L] to
4.3g/L [0.9-12.9g/L], P .019; 6months, 1.2g/L
[0.1-4.1 g/L] to 2.4 g/L [0.1-12.4 g/L], P  .004;
Fig 1). These data are consistent with the results of our
previous study.5 Overall, resting TAT decreased over the
time course of the study, becoming significantly lower by 6
months (P  .004).
On subgroup analysis, there was a significant fourfold
reduction in resting TAT levels over the 6-month study
period in subjects randomized to BMT plus PTA (median
[IQR] TAT, 6.4 g/L [2.7-13.5 g/L] to 1.5 g/L
[0.3-2.9 g/L]; P  .038). There was no significant
reduction in TAT in either the BMT-alone group (median
[IQR] TAT, 1.9 g/L [1.8-11.5 g/L] to 1.8 g/L
[0.5-6.9 g/L]; P  .138) or the BMT plus supervised
exercise group (median [IQR] TAT, 2.4 g/L [0.9-4.0
g/L] to 1.6 g/L [0.1-3.5 g/L]; P  .249; Fig 2). In
the BMT plus PTA group, the improvements observed in
TAT showed a significant correlation with the improve-
ment in ABPI (Spearman coefficient, 0.676; P  .045).
In addition to reduced resting TAT levels, there was a
positive trend toward reduced postexercise TAT levels over
the 6-month period in the BMT plus PTA group (median
postexercise [IQR] TAT, 10.2 g/L [3.5-13.8 g/L] to
3.7 g/L [0.8-6.7 g/L]; P  .066). No change in
dication distance, and absolute claudication distance
6 mo P value*
0.79 (0.68-0.93) .012
0.70 (0.62-0.84) .75
0.70 (0.65-0.78) .46
0.93 (0.90-1.01) .013
124 (57-774) .001
56 (45-325) .075
92 (47-169) .074
698 (147-1000) .011
217 (115-1000) .001
145 (75-435) .12
124 (74-352) .35
698 (212-1000) .008
exercise; PTA, percutaneous transluminal balloon angioplasty; ICD, initialclau
eriod
visedpostexercise TAT levels was observed in either the BMT-
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[2.4-39.5 g/L] to 16.2 g/L [2.8-29.6 g/L]; P 
.500) or the BMT plus supervised exercise group (median
postexercise [IQR] TAT, 7.4 g/L [2.2-11.0 g/L] to
6.2 g/L [0.1-9.7 g/L]; P  .345).
Fibrinolysis: PAI-1 antigen
No correlation between baseline PAI-1 antigen levels
and disease or symptom severity was found. There was no
significant difference in baseline PAI-1 antigen levels
among the three groups (P .21; ANOVA). On subgroup
analysis, a significant reduction in PAI antigen levels was
observed in subjects in the BMT plus PTA group (median
[IQR] PAI antigen, 10.0 ng/mL [1.0-20.5 ng/mL] to 1.0
ng/mL [1.0-14.8 ng/mL]; P  .043) at 6 months com-
pared with baseline. This reduction in PAI antigen levels
showed a significant correlation with the percentage im-
provement in ACD (Spearman coefficient, 0.696; P 
.039) and the improvement in ABPI (Spearman coefficient,
0.856; P .003). There were no significant changes in PAI
antigen levels in the BMT group (median [IQR] PAI
antigen, 20.0 ng/mL [3.0-34 ng/mL] to 16.5 ng/mL
[7.3-42.5 ng/mL]; P  .686) or in the BMT plus super-
vised exercise group (median [IQR] PAI antigen, 15.0
ng/mL [2.5-20.5 ng/mL] to 9.5 ng/mL [1.0-18.8 ng/
mL]; P  1.00).
DISCUSSION
The UK HTA-funded prospective randomized con-
trolled EXACT has demonstrated—to our knowledge, for
the first time—that lower limb revascularization by PTA in
patients with mild to moderate unilateral IC due to infrain-
guinal disease results in an improvement in the resting
procoagulant and hypofibrinolytic state as demonstrated by
Fig 1. Change in thrombin-antithrombin (TAT) complex levels
after exercise to absolute claudication distance over time for all
subjects. The Wilcoxon signed rank test was used to compare
changes in TAT over time.a reduction in TAT levels and PAI-1 antigen levels in themedium term. Furthermore, these changes correlate well
with the observed improvement in ABPI and ACD. Be-
cause similar changes in TAT and PAI-1 antigen were not
observed in patients randomized to continue with BMT
alone or to receive BMT plus supervised exercise, we be-
lieve that these novel data support the working hypothesis.
Specifically, they suggest that PTA, but not BMT or BMT
plus supervised exercise, leads to an improvement in the
procoagulant diathesis observed in this patient group be-
cause it alone leads to an improvement in resting leg blood
flow and a reduction in calf muscle ischemia/reperfusion
on exercise.
It is well established that PAD is associated with a
procoagulant and hypofibrinolytic state, as demonstrated
by increased levels of fibrinogen,12 D-dimer,13 prothrombin
fragment 1 and 2, TAT,13,14 PAI-1 antigen, and tissue plas-
minogen activator antigen15 and that the severity of this
hypercoagulable state may correlate with disease severity.14,15
In response to moderate to heavy exercise, normal controls
demonstrate activation of coagulation that is well balanced
by activation of the fibrinolytic system.16 Previous work
from our group has shown that this exercise-induced acti-
vation of coagulation is exacerbated in patients with IC,
with increases in TAT detectable immediately after exercise
to ACD. This results in significantly higher postexercise
TAT levels compared with age- and sex-matched controls.5
These findings that are similar to those shown in other
studies of subjects with other cardiovascular diseases.17
Although our previous study failed to demonstrate an
improvement in fibrinolysis,5 several other studies have
suggested that fibrinolysis may be enhanced after acute
exercise.17,18 This disparity may be due to the different
Fig 2. Change in resting thrombin-antithrombin (TAT) com-
plex levels between 0 and 6 months for each of the treatment
groups. The Wilcoxon signed rank test was used to compare
changes in TAT over time. BMT, Best medical therapy; SE, super-
vised exercise; PTA, percutaneous transluminal balloon angio-
plasty.intensity and duration of exercise in these studies.
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ease—in particular, PAD—have a prothrombotic tendency
are not well understood. One possible explanation in pa-
tients with IC is based on the important observation that
when such patients walk (and then rest because of pain),
they experience IRI of the leg muscles, which, in turn, leads
to an acute increase in inflammatory markers.19,20 It has
been suggested that IRI and the inflammatory response
within the leg muscles during exercise leads to endothelial
cell activation and injury, as demonstrated by increased
levels of endothelial products such as von Willebrand fac-
tor.14,21 this in turn leads to the activation of the coagula-
tion system. Exercise training may lead to an attenuation of
some elements of this systemic inflammatory response in
healthy individuals17 and patients.22 The effect of exercise
training, however, on thrombin production in subjects
with coronary heart disease is equivocal and has not been
evaluated in PAD. With regard to fibrinolysis, only one
nonrandomized study has demonstrated enhanced endog-
enous fibrinolysis after 6 months of exercise training.23
Successful PTA in patients with IC has been shown to
be associated with an immediate increase in fibrin turnover,
most probably secondary to endothelial cell activation.24,25
However, no study to date has examined the medium- and
long-term effects of PTA on coagulation and fibrinolysis in
patients with IC. One study assessing the effect of surgical
revascularization on coagulant activity demonstrated no
change in the preoperative coagulation and fibrinolytic
defects.26 It is important to note, however, that all subjects
in the study had critical limb ischemia, and follow-up was
performed only to 30 days.
The findings of this study provide novel insights into
the pathophysiology of cardiovascular risk in patients with
IC. Patients randomized to remain on BMT or to BMT
plus participation in a 12-week supervised exercise program
showed no significant improvement in their resting proco-
agulant diathesis. In contrast, subjects randomized to BMT
plus PTA demonstrated a significant improvement in their
thrombotic tendency that was associated with clear evi-
dence of improved limb perfusion and symptoms. Further-
more, BMT plus PTA seemed to attenuate the acute hyper-
coagulable response observed after treadmill testing to
ACDwhen compared with BMT alone or BMT plus super-
vised exercise. This attenuation occurred despite the almost
fourfold improvement in ACD observed in the BMT plus
PTA group.
The data from this study strongly support, but do not
prove, the working hypothesis that both the chronic con-
stitutive and acute postexercise procoagulant state ob-
served in patients with IC are a consequence of reduced
lower limb perfusion and the resulting IRI developed upon
walking and then resting. Themost likely underlyingmech-
anism would seem to be endothelial cell damage and acti-
vation. This hypothesis is supported by the observation that
compared with healthy controls, patients with PAD dem-
onstrate activation of coagulation that is associated with
endothelial cell activation14 and disease severity.27 Treat-
ments such as PTA (and, presumably, also surgery) thatrestore (nearly) normal perfusion obtund this IRI and thus
attenuate both the resting procoagulant diathesis and the
response to acute exercise. In contrast, other treatments such
as (supervised) exercise and specific pharmacotherapy—
which, although effecting symptomatic improvement
through as yet incompletely defined mechanisms, do not
alter the underlying hypoperfusion and IRI—may not af-
fect the acute on chronic procoagulant diathesis observed
in these patients.
This study failed to show significant symptomatic im-
provements in subjects randomized to supervised exercise.
Although this may be a consequence of the design of the
exercise program, its twice-weekly nature (augmented by
unsupervised home exercise), and its 12-week duration,
pilot data show that the intensity of exercise and the train-
ing effect observed should have been sufficient to produce
improvements in walking distance. Indeed, these pilot
studies and other clinical data have shown improvements of
up to 94% in ACD after this exercise program. The lack of
an observed treatment effect of BMT plus supervised exer-
cise may, therefore, be an example of a type II statistical
error, especially because this science study, nested within a
larger clinical trial, was not aimed at or powered to consider
walking distance as an end point. Although this study has
demonstrated a significant benefit of PTA, we have not
been able to fully establish the effect of supervised exercise
and BMT on the resting procoagulant state. Although
these did not reach significance, we observed a positive
trend for both thrombin production and fibrinolysis with
BMT plus supervised exercise and, to a lesser extent, with
BMT alone. Although it is clear that the magnitude of this
change is significantly less than that observed with PTA, it
is possible that a larger study would confirm a positive
benefit for supervised exercise on the prothrombotic dia-
thesis. Indeed, a larger nonrandomized study by Killewich
et al23 previously demonstrated a significant 23% improve-
ment in PAI activity after 6 months of supervised exercise.
The effect of supervised exercise and pharmacotherapy on
thrombin production and fibrinolysis is currently the sub-
ject of an ongoing randomized controlled study.
Building on the observational platform provided by the
present original data, further studies will be aimed at con-
firming or refuting the original hypothesis. By improving
the acute or chronic prothrombotic diathesis, PTA has the
potential not only to improve walking distance, but also to
reduce morbidity and mortality due to thrombotic vascular
events. However, these longer-term clinical benefits and
the durability of the benefits already observed will need to
be established in much larger prospective longitudinal
studies comparing treatments that do (surgery or angio-
plasty) and do not (pharmacotherapy or supervised exer-
cise) revascularize the limb.
Firm conclusions from this randomized study are lim-
ited by the small numbers of patients and require corrobo-
ration in a larger cohort. However, if confirmed, they
suggest that a more aggressive approach to IC due to
infrainguinal disease may have a positive effect on cardio-
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January 200646 Hobbs et alvascular risk and symptomatic status in this group of pa-
tients.
We would like to thank Mark Hill, Department of
Haematology, for his help in performing the TAT and
PAI-1 antigen ELISAs. We would also like to thank Pro-
fessor Paul Robinson, Faculty of Health & Exercise at
University College Worcester, for his assistance in design-
ing and piloting the exercise program.
AUTHOR CONTRIBUTIONS
Conception and design: SDH, CF, DJA, AWB
Data collection: SDH
Analysis and interpretation: SDH, CF, DJA, AWB
Writing the article: SDH
Critical revision of the article: CF, DJA, AWB
Final approval of the article: SDH, TM, CF, DJA, AWB
Statistical analysis: SDH, TM
Obtained funding: SDH, CF, AWB
Overall responsibility: SDH
REFERENCES
1. Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV,
Prescott RJ. Edinburgh Artery Study: prevalence of asymptomatic and
symptomatic peripheral arterial disease in the general population. Int J
Epidemiol 1991;20:384-92.
2. Smith GD, Shipley MJ, Rose G. Intermittent claudication, heart disease
risk factors, and mortality. The Whitehall Study. Circulation 1990;82:
1925-31.
3. Murabito JM, D’Agostino RB, Silbershatz H, Wilson PWF. Intermit-
tent claudication: a risk profile from the Framingham Heart Study.
Circulation 1997;96:44-9.
4. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, Mc-
Cann TJ, et al. Mortality over a period of 10 years in patients with
peripheral arterial disease. N Engl J Med 1992;326:381-6.
5. Burns PJ, Wilmink ABM, Fegan C, Bradbury AW. Exercise in claudi-
cants is associated with excessive thrombin generation. Eur J Vasc
Endovasc Surg 2003;26:150-5.
6. Leng GC, Fowkes FGR. The Edinburgh Claudication Questionnaire:
an improved version of the WHO/Rose Questionnaire for use in
epidemiological surveys. J Clin Epidemiol 1992;45:1101-9.
7. TransAtlantic Inter-Society Consensus (TASC). Clinical evaluation of
intermittent claudication. Eur J Vasc Endovasc Surg 2001;19(Suppl
A):S48-63.
8. Burns P, Gough S, Bradbury AW. Management of peripheral arterial
disease in primary care. Br Med J 2003;326:584-8.
9. TransAtlantic Inter-Society Consensus (TASC). Management of pe-
ripheral arterial disease—femoropopliteal PTA. Eur J Vasc Endovasc
Surg 2000;19(Suppl A):S88-91.
10. Gardner AW, Poehlman ET. Exercise rehabilitation programs for
the treatment of claudication pain. A meta-analysis. JAMA 1995;274:11. Baglin T. The measurement and application of thrombin generation.
Br J Haematol 2005;130:653-61.
12. Lassila R, Peltonen S, Lepantalo M, Saarinen O, Kauhanen P, Manni-
nen V. Severity of peripheral atherosclerosis is associated with fibrino-
gen and degradation of cross-linked fibrin. Arterioscler Thromb 1993;
13:1738-42.
13. De Buyzere M, Philippe J, Duprez D, Baele G, Clement DL. Coagula-
tion system activation and increase of D-dimer levels in peripheral
arterial occlusive disease. Am J Hematol 1993;43:91-4.
14. Cassar K, Bachoo P, Ford I, Greaves M, Brittenden J. Markers of
coagulation activation, endothelial stimulation and inflammation in
patients with peripheral arterial disease. Eur J Vasc Endovasc Surg
2005;29:171-6.
15. Killewich LA, Gardner AW, Macko RF, Hanna DJ, Goldberg AP, Cox
DK, et al. Progressive intermittent claudication is associated with im-
paired fibrinolysis. J Vasc Surg 1998;27:645-50.
16. Weiss C, Seitel G, Bartsch P. Coagulation and fibrinolysis after moder-
ate and very heavy exercise in healthy male subjects. Med Sci Sports
Exerc 1998;30:246-51.
17. Womack CJ, Nagelkirk PR, Coughlin AM. Exercise-induced changes in
coagulation and fibrinolysis in healthy populations and patients with
cardiovascular disease. Sports Med 2003;33:795-807.
18. Mustonen P, Lepantalo M, Lassila R. Physical exertion induces throm-
bin formation and fibrin degradation in patients with peripheral athero-
sclerosis. Arterioscler Thromb Vasc Biol 1998;18:244-9.
19. Tisi PV, Shearman CP. Biochemical and inflammatory changes in the
exercising claudicant. Vasc Med 1998;3:189-98.
20. Turton EP, Coughlin PA, Kester RC, Scott DJ. Exercise training
reduces the acute inflammatory response associated with claudication.
Eur J Vasc Endovasc Surg 2002;23:309-16.
21. Smith FB, Lee AJ, Hau CM, Rumley A, Lowe GD, Fowkes FG. Plasma
fibrinogen, haemostatic factors and prediction of peripheral arterial
disease in the Edinburgh Artery Study. Blood Coagul Fibrinolysis
2000;11:43-50.
22. Tisi PV, Hulse M, Chulakadabba A, Gosling P, Shearman CP. Exercise
training for intermittent claudication: does it adversely affect biochem-
ical markers of the exercise-induced inflammatory response? Eur J Vasc
Endovasc Surg 1997;14:344-50.
23. Killewich LA, Macko RF, Montgomery PS, Wiley LA, Gardner AW.
Exercise training enhances endogenous fibrinolysis in peripheral arterial
disease. J Vasc Surg 2004;40:741-5.
24. Jorgensen B, Nielsen JD,Helligso P, BaekgaardN, EgebladM. Throm-
bosis and intrinsic fibrinolysis in percutaneous transluminal angioplasty.
Eur J Vasc Surg 1994;8:264-9.
25. Woodburn KR, Lowe GD, Pollock JG, Rumley A, Reid AW. Percuta-
neous angioplasty, endothelial markers, and fibrin turnover. J Endovasc
Surg 1994;1:53-60.
26. Parsson H, Holmberg A, Siegbahn A, Bergqvist D. Activation of
coagulation and fibrinolytic systems in patients with CLI is not normal-
ized after surgical revascularisation. Eur J Vasc Endovasc Surg 2004;27:
186-92.
27. Woodburn KR, Lowe GD, Rumley A, Love J, Pollock JG. Relation of
haemostatic, fibrinolytic, and rheological variables to the angiographic
extent of peripheral arterial occlusive disease. Int Angiol 1995;14:
219-25.975-80. Submitted Jul 7, 2005; accepted Sep 8, 2005.
AVAILABILITY OF JOURNAL BACK ISSUES
As a service to our subscribers, copies of back issues of Journal of Vascular Surgery for the preceding
5 years are maintained and are available for purchase fromMosby until inventory is depleted. Please write
to Elsevier Inc., Subscription Customer Service, 6277 Sea Harbor Dr, Orlando, FL 32887, or call
800-654-2452 or 407-345-4000 for information on availability of particular issues and prices.
